Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Autor:	Gitelman, Stephen E, Bundy, Brian N, Ferrannini, Ele, Lim, Noha, Blanchfield, J Lori, DiMeglio, Linda A, Felner, Eric I, Gaglia, Jason L, Gottlieb, Peter A, Long, S Alice, Mari, Andrea, Mirmira, Raghavendra G, Raskin, Philip, Sanda, Srinath, Tsalikian, Eva, Wentworth, John M, Willi, Steven M, Krischer, Jeffrey P, Bluestone, Jeffrey A, Gleevec Trial Study Group
Rok vydání:	2021
Předmět:	Blood Glucose Adult Male Adolescent Clinical Trials and Supportive Activities Clinical Sciences Medical Biochemistry and Metabolomics Gleevec Trial Study Group Autoimmune Disease Young Adult Double-Blind Method Clinical Research Diabetes Mellitus Humans Protein Kinase Inhibitors Metabolic and endocrine Prevention Diabetes Evaluation of treatments and therapeutic interventions Middle Aged Prognosis 6.1 Pharmaceuticals Imatinib Mesylate Public Health and Health Services Female Biomarkers Type 1 Follow-Up Studies
Zdroj:	The lancet. Diabetes & endocrinology, vol 9, iss 8
Popis:	BackgroundType 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.MethodsWe did a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Patients with recent-onset type 1 diabetes (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od_______325::0b6017dd19e135e30be952bcf76cb1c2 https://escholarship.org/uc/item/2hr6m8qw Zobrazit plný text záznamu